NCT06840002 - A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

July 31, 2026

Conditions

Ovarian Cancer

Interventions

DRUG

SHR-A1811

SHR-A1811.

DRUG

Carboplatin

Carboplatin.

DRUG

Bevacizumab

Bevacizumab.

DRUG

Oxaliplatin for Injection

Oxaliplatin for injection.

DRUG

Paclitaxel injection

Paclitaxel injection.

DRUG

Doxorubicin hydrochloride liposome injection

Doxorubicin hydrochloride liposome injetction.

DRUG

Adebrelimab Injection

Adebrelimab injection.

Trial Locations (1)

RECRUITING

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors

lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY